Inhibitors of TRAF6 have shown promise in inhibiting HCC growth, and combining a TRAF6 inhibitor with a PD-1 blocker has yielded enhanced therapeutic outcomes 102. Here, TRAF6 is linked to hepatocellular carcinoma.